Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Efstathios Karathanasis · CASE WESTERN RESERVE UNIVERSITY · 2024 · $77,121 — PROJECT SUMMARY: Cancer immunotherapy is based on the premise of immune-recognition and targeted killing of tumor cells, thus possesses the promising power to eradicate aggressive disease. Notably to date, immunotherapy with immune checkpoint inhibitors significantly prolongs the survival of patient…
YI-FEN LEE · UNIVERSITY OF ROCHESTER · 2024 · $449,295 — We propose to study extracellular vesicles (EVs) as novel mediators of the pathogenesis of radiation cystitis (RC), which affects approximately 15% of prostate cancer (PCa) patients treated with radiotherapy (RT). Bladder radiotoxicity impacts the lives of PCa survivors, most notably older patients,…
Josiane Fofana · BOSTON UNIVERSITY MEDICAL CAMPUS · 2024 · $23,060 — PROJECT SUMMARY/ABSTRACT HIV remains a global threat despite the tremendous progress of combinatorial antiretroviral therapy (cART). Chronic inflammation and immune activation support an increased risk of non-AIDS co-morbidities in cART- treated HIV patients. This condition is attributed to various …
BORRIES DEMELER · UNIVERSITY OF MONTANA · 2024 · $586,559 — Project Summary/Abstract: We request funding for a Beckman Optima AUC analytical ultracentrifuge equipped with Rayleigh interference and multi-wavelength UV-visible absorption detection, including required accessories, This instrument will be integrated into the Center for Biomolecular Structure and…
KEBIN LIU · CHARLIE NORWOOD VA MEDICAL CENTER · 2024 — Project Summary IFN was an FDA-approved agent for human cancer therapy and is currently used as exogenous recombinant protein or protein prodrugs. The use of IFN in human cancer therapy has been limited by the ineffective dosing and high toxicity. This proposal develops a lipid nanoparticle encap…
Jonathan Henry Shannahan · PURDUE UNIVERSITY · 2024 · $337,723 — Project Summary / Abstract Individuals with metabolic syndrome (MetS) compose a significant and growing proportion of our U.S. and global population (> 25%). It has been established that the presence of chronic diseases, such as MetS, enhances and prolongs environmental exposure-induced inflammation…
Craig Lewis Duvall · VANDERBILT UNIVERSITY · 2024 · $595,117 — PROJECT SUMMARY/ABSTRACT RNA interference (RNAi) using short interfering RNA (siRNA) is a promising strategy to block disease- causing targets that are difficult to selectively and/or potently block with conventional small molecule drugs. Five siRNA drugs are now in clinical use, all gaining FDA ap…
William H. Peranteau · CHILDREN'S HOSP OF PHILADELPHIA · 2024 · $705,491 — PROJECT SUMMARY Metabolic liver diseases are the second most common indication for a pediatric liver transplant. Hereditary tyrosinemia type I (HT1) is a metabolic liver disease that results from FAH gene mutations causing a deficiency in fumarylacetoacetate hydrolase (FAH), the last enzyme in the t…
Sandeep K Agarwal · BAYLOR COLLEGE OF MEDICINE · 2024 · $556,482 — Project Summary/Abstract. Scleroderma (systemic sclerosis, SSc) is a progressive multisystem, autoimmune fibrotic disease with a high morbidity and mortality. SSc associated interstitial lung disease is a leading cause of death. Despite important advances in our understanding of SSc, treatment optio…
Daniel John Siegwart · UT SOUTHWESTERN MEDICAL CENTER · 2024 · $372,136 — Project Summary The programmable CRISPR/Cas gene editing system has great potential for cancer treatment due to the ability to precisely inactivate or repair cancer-related genes. However, delivery of CRISPR to solid tumors for efficient cancer therapy remains limited by the uniquely stiff and fibro…
T. Jake Liang · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2024 · $2,063,799 — Despite the development of highly effective HCV treatments, an effective prophylactic vaccine is still lacking. HCV infection is mediated by its envelope glycoproteins E1 and E2 in the entry process with E2 binding to cell receptors and E1 mediating endosomal fusion. The structure of E1E2 has only b…
Elizabeth Ottinger · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · 2024 · $1,066,904 — We have engaged in productive partnerships across various therapeutic areas in collaboration with NIH and external academic researchers and companies. During the current fiscal year, progress was made in meeting the objectives of these various collaborations. The team is further refining the high-co…
Edward Wu · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · 2024 · $1,874,696 — The small interfering RNA (siRNA) is carefully encapsulated within polymeric nanoparticles, which have been demonstrated to successfully deliver the therapeutic agent to endosomes specifically in spinal cord dorsal horn neurons following intrathecal administration. Extensive proof-of-concept efficac…
Curtis Harris · DIVISION OF BASIC SCIENCES - NCI · 2024 · $2,600,582 — In collaboration with Dr. Carl June (University of Pennsylvania), we have generated the d133p53a-armored CAR-T cells and revealed that they show superior anti-tumor activity compared with the control CAR-T cells (KIMRIAH(registered trademark) in clinical use) in co-culture and mouse injection models…
Andre LaRochelle · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · 2024 · $1,497,052 — 1. Addressing the Cellular Scarcity in FA 1.1 Eltrombopag to Enhance Marrow HSPCs. We have identified eltrombopag (EPAG), a small molecule agonist of the thrombopoietin receptor c-MPL, as a transformative therapeutic approach to augment the availability of HSPCs in FA patients. EPAG enhances DNA r…
David M Koelle · UNIVERSITY OF WASHINGTON · 2021 · $561,763 — Project Summary: The waning of immunity has a major impact on morbidity and mortality in the aged. Antigen-specific, acquired, and especially T-cellular is important in host defense against chronic intracellular pathogens and cancer. Infections with these microbes and skin cancers with high mutation…
JOSEPH M FOX · UNIVERSITY OF DELAWARE · 2021 · $2,359,432 — Project Summary The goal of this Center of Biomedical Research Excellence is to continue our efforts to develop molecular approaches for probing biology, to discover and apply new chemical biology tools for the study of biological pathways associated with disease, and to develop computational approa…
Shane P Crotty · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2021 · $790,753 — Project Summary Preclinical studies and early stage human trials evaluating passively transferred broadly neutralizing antibodies (bnAbs) suggest that a vaccine capable of eliciting bnAbs would provide effective protection from HIV infection. However, the difficulty of inducing bnAbs through vaccina…
DANIEL G ANDERSON · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2021 · $568,747 — Many HIV vaccine candidates have failed clinical trials, as they were unable to elicit a potent and durable response to HIV viral challenge. Broadly neutralizing antibodies (bnAbs) have been identified in a number of HIV+ individuals with well-controlled viral levels, and these bnAbs target epitopes…
Graham Temples · PURILOGICS, LLC · 2021 · $977,854 — Project Summary This SBIR Direct to Phase II project will develop the first affinity membrane for purifying mRNA with high capacity, selectivity, and throughput. mRNA medicines have the potential to address a wide variety of pathologies. FDA emergency use authorizations for two mRNA-based COVID-19 v…